Results 81 to 90 of about 106,112 (301)

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome

Scientific Reports, 2023
Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19.
Neven Mohamed Sarhan, Ahmed Essam Abou Warda, Haytham Soliman Ghareeb Ibrahim, Mona Farag Schaalan, Shaimaa Mohamed Fathy   +4 more
doaj   +1 more source

Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease

American Journal of Hematology, EarlyView.
ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt, Sanjay R. Thakoerdin, Maud Zwolsman, Gaby Stegemann, Hanke Matlung, Taco W. Kuijpers, Bart J. Biemond, Karin Fijnvandraat, Robin van Bruggen, Erfan Nur   +9 more
wiley   +1 more source

Herpes Zoster After Tocilizumab Therapy in COVID-19 Survivor: A Case Report

Acta Medica Indonesiana, 2022
The COVID-19 pandemic has become a concern for the world community. However, despite abundant attempts taking place, there is currently no definitive therapy for COVID-19 yet.
Suwenny Suwenny, Sahat Halim
doaj   +2 more sources

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. [PDF]

, 2020
The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2.
Ansari, Aftab A, Ceribelli, Angela, De Santis, Maria, Gershwin, M Eric, Motta, Francesca, Ridgway, William M, Selmi, Carlo   +6 more
core  

Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. [PDF]

, 2015
Takayasu arteritis (TA) is an idiopathic large-vessel vasculitis affecting the aorta and its major branches. Although the disease rarely affects children, it does occur, even in infants.
Al-Obaidi, M, Brogan, PA, Dolezalova, P, Eleftheriou, D, McMahon, AM, Varnier, G   +5 more
core   +1 more source

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. [PDF]

, 2020
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%.
Amin, Alpesh N, Chang, Yongen, Cheng, Timmy T, Choi, Grace, Ferrey, Antoney J, Gohil, Shruti, Hanna, Ramy M, Hsieh, Lanny, Huang, Susan S, Ivaturi, Kaushik, Kalantar-Zadeh, Kamyar, Lau, Wei Ling, Lee, Richard A, Nguyen, Lawrence, Park, Elisa, Reddy, Uttam, Rhee, Connie M, Tantisattamo, Ekamol, Tonthat, Sam, Wang, Brian   +19 more
core   +1 more source

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? [PDF]

, 2017
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA).
A Ferreiro-Iglesias, A Groof De, A Kavanaugh, A Montes Marquez, a N Burska, A Obry, A Pachot, A Picchianti Diamanti, A Ruyssen-Witrand, AP Treschow, AP Trouvin, B Bresnihan, B Mesko, B Möller, BVJ Cuppen, C a Wijbrandts, C Castro-Villegas, C Enevold, C Potter, C Trocmé, CM Weyand, CP Mavragani, D Plant, D Plant, D Plant, D-Y Chen, DA Pappas, DF McWilliams, DS Gibson, Edward M. Vital, EM Vital, F Breedveld, G Dennis, G Dennis Jr, G Ferraccioli, G Morozzi, GS Firestein, H Canhão, H Marotte, H-P Brezinschek, HG Raterman, HL Wright, I Acosta-Colman, I González-Alvaro, I Gutierrez-Roelens, I Ortea, I Ortea, IY Choi, J Adriaansen, J Cui, J Ducreux, J Holten van, J Holten van, J Inciarte-Mundo, J Kikuchi, J Oliver, J Pieper, J Sellam, J Sellam, J Sellam, J Sellam, J Wang, J Wang, JAB Nies van, JD Cañete, JD Isaacs, JE Gottenberg, JL Nam, João Eurico Fonseca, JT Joensuu, JW Whitaker, K Chatzidionysiou, K Hambardzumyan, K Kayakabe, K Klein, K Owczarczyk, K Shimamoto, K Uno, K Vos, KL Hyrich, KL Hyrich, L Mancarella, LE Kristensen, LG Baarsen van, LGM Baarsen Van, M Abildtrup, M Ammari, M Nakou, M Scarsi, M Scarsi, M Umemura, Maya H. Buch, MH Buch, MH Buch, MH Buch, MH Stradner, MJ Leandro, MJ Townsend, MK Crow, MK Söderlin, P Roll, PA Schouwenburg van, PP Tak, R Klaasen, R Priori, RJ Maneiro, RM Thurlings, RM Thurlings, S Alzabin, S Das, S Dass, S Fabre, S Fabre, S Iwata, S Kelly, S Kubo, S Nakamura, S Rosengren, S Saevarsdottir, S Visvanathan, S Visvanathan, S Vosslamber, S-Y Kawashiri, SB Krintel, SC Nair, SK Sieberts, SL Smith, SL Smith, SR Kapoor, TC Pouw Kraan van der, TJM Smeets, U Meusch, V Badot, Vasco C. Romão, VE Hogan, W Hueber, Y Sanayama, Y-M Pers, YH Lee, YKO Teng, Z Mahmood   +140 more
core   +3 more sources

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source